Canadian Markets closed

MediciNova, Inc. (MNOV)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
5.42-0.01 (-0.18%)
At close: 4:00PM EDT

5.42 0.00 (0.00%)
After hours: 5:20PM EDT

People also watch
Full screen
Previous Close5.43
Bid5.24 x 1600
Ask10.53 x 500
Day's Range5.38 - 5.57
52 Week Range4.85 - 7.78
Avg. Volume45,211
Market Cap187.21M
PE Ratio (TTM)-17.54
EPS (TTM)-0.31
Earnings DateApr 26, 2017 - May 1, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

    LA JOLLA, Calif., June 05, 2017-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that Associate Professor ...

  • Zacks Small Cap Research5 months ago

    MNOV: MN-166 Making Progress in Numerous Indications…

    There have been a number of recent announcements regarding MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. - On February 7, 2017, MediciNova, Inc. (MNOV) announced that an abstract regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, which is taking place from Apr. 22-28, 2017 in Boston, Massachusetts. - On December 20, 2016, MediciNova announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) for MN-166 for the treatment of ALS.

  • Zacks Small Cap Research7 months ago

    MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion

    On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.